Protein crystallography and fragment-based drug design.
暂无分享,去创建一个
Rocco Caliandro | R. Caliandro | M. de Candia | D. Belviso | B. Aresta | C. Altomare | Brunella Maria Aresta | Danilo Benny Belviso | Modesto de Candia | Cosimo Damiano Altomare
[1] Sandor Vajda,et al. Characterization of protein-ligand interaction sites using experimental and computational methods. , 2006, Current opinion in drug discovery & development.
[2] James M. Woolven,et al. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. , 2012, Journal of medicinal chemistry.
[3] Yasser Heakal,et al. Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma , 2011, The Annals of pharmacotherapy.
[4] Brian Pease,et al. Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography† , 2009, Journal of medicinal chemistry.
[5] C. Giacovazzo,et al. A practical study of the electron‐density‐map variance , 2012 .
[6] N. Henderson,et al. The regulation of inflammation by galectin‐3 , 2009, Immunological reviews.
[7] D. J. Peake,et al. Improved count rate corrections for highest data quality with PILATUS detectors , 2012, Journal of synchrotron radiation.
[8] Randy J. Read,et al. Using SAD data in Phaser , 2011, Acta crystallographica. Section D, Biological crystallography.
[9] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[10] E. Drioli,et al. Direct production of carbamazepine–saccharin cocrystals from water/ethanol solvent mixtures by membrane-based crystallization technology , 2011 .
[11] Gianni Chessari,et al. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. , 2008, Journal of medicinal chemistry.
[12] M. Akke,et al. The Carbohydrate-Binding Site in Galectin-3 Is Preorganized To Recognize a Sugarlike Framework of Oxygens: Ultra-High-Resolution Structures and Water Dynamics , 2011, Biochemistry.
[13] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[14] Kenichiro Fujiwara,et al. In-crystal affinity ranking of fragment hit compounds reveals a relationship with their inhibitory activities , 2011 .
[15] R. Godemann,et al. Fragment-based discovery of BACE1 inhibitors using functional assays. , 2009, Biochemistry.
[16] Peter Main,et al. Histogram matching as a new density modification technique for phase refinement and extension of protein molecules , 1990 .
[17] Paul Emsley,et al. Handling ligands with Coot , 2012 .
[18] Aaron J. Oakley,et al. Fragment-Based Screening by Protein Crystallography: Successes and Pitfalls , 2012, International journal of molecular sciences.
[19] A. Gibbs,et al. Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[20] Hsiao-Chin Hong,et al. Galectin-1-Mediated Tumor Invasion and Metastasis, Up-Regulated Matrix Metalloproteinase Expression, and Reorganized Actin Cytoskeletons , 2009, Molecular Cancer Research.
[21] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[22] A. Welm,et al. Modulation of Glucose Transporter 1 (GLUT1) Expression Levels Alters Mouse Mammary Tumor Cell Growth In Vitro and In Vivo , 2011, PloS one.
[23] Munish Puri,et al. Molecular recognition of physiological substrate noradrenaline by the adrenaline-synthesizing enzyme PNMT and factors influencing its methyltransferase activity. , 2009, The Biochemical journal.
[24] W. Guida,et al. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. , 2012, Journal of medicinal chemistry.
[25] R. Kiss,et al. Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells. , 2008, Journal of medicinal chemistry.
[26] G. Klebe,et al. Experimental and Computational Active Site Mapping as a Starting Point to Fragment‐Based Lead Discovery , 2012, ChemMedChem.
[27] Benedetta Carrozzini,et al. Advances in the EDM-DEDM procedure. , 2009, Acta crystallographica. Section D, Biological crystallography.
[28] W N Hunter,et al. Structure of trypanothione reductase from Crithidia fasciculata at 2.6 A resolution; enzyme-NADP interactions at 2.8 A resolution. , 1994, Acta crystallographica. Section D, Biological crystallography.
[29] Robert M Stroud,et al. A general protocol for the crystallization of membrane proteins for X-ray structural investigation , 2009, Nature Protocols.
[30] Frank Guarnieri,et al. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). , 2011, Bioorganic & medicinal chemistry letters.
[31] David M. Wilson,et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.
[32] Karl Edman,et al. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.
[33] Astrid Zimmermann,et al. Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90. , 2012, Bioorganic & medicinal chemistry letters.
[34] G. Rabinovich,et al. Galectins: structure, function and therapeutic potential , 2008, Expert Reviews in Molecular Medicine.
[35] C. Giacovazzo,et al. Ab initio phasing of proteins with heavy atoms at non-atomic resolution: pushing the size limit of solvable structures up to 7890 non-H atoms in the asymmetric unit , 2008 .
[36] Xiaofeng Jiang,et al. Galectin-3 Targeted Therapy with a Small Molecule Inhibitor Activates Apoptosis and Enhances Both Chemosensitivity and Radiosensitivity in Papillary Thyroid Cancer , 2009, Molecular Cancer Research.
[37] A. Sharff,et al. High-throughput crystallography to enhance drug discovery. , 2003, Current opinion in chemical biology.
[38] M. Romano,et al. β‐D‐Glucosyl Conjugates of Highly Potent Inhibitors of Blood Coagulation Factor Xa Bearing 2‐Chorothiophene as a P1 Motif , 2012, ChemMedChem.
[39] Pawel Grochulski,et al. MxDC and MxLIVE: software for data acquisition, information management and remote access to macromolecular crystallography beamlines. , 2012, Journal of synchrotron radiation.
[40] Judith D. Cohn,et al. Automated ligand fitting by core-fragment fitting and extension into density , 2006, Acta crystallographica. Section D, Biological crystallography.
[41] S. Barondes,et al. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. , 1998, The Journal of biological chemistry.
[42] Glyn Williams,et al. Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.
[43] G. Kleywegt,et al. Density modification: theory and practice , 2001 .
[44] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[45] Jon Winter,et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. , 2012, Journal of medicinal chemistry.
[46] Benedetta Carrozzini,et al. Molecular replacement: the probabilistic approach of the program REMO09 and its applications. , 2009, Acta crystallographica. Section A, Foundations of crystallography.
[47] Hoan Vu,et al. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. , 2010, The Biochemical journal.
[48] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[49] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[50] B. Shoichet,et al. Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.
[51] V. Nienaber,et al. Fragment-Based Screening for Inhibitors of PDE4A Using Enthalpy Arrays and X-ray Crystallography , 2012, Journal of biomolecular screening.
[52] Gavin Hirst,et al. Fragment-based discovery of JAK-2 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[53] Maria Cristina Burla,et al. The difference electron density: a probabilistic reformulation. , 2010, Acta crystallographica. Section A, Foundations of crystallography.
[54] Meitian Wang,et al. Radiation damage in room-temperature data acquisition with the PILATUS 6M pixel detector , 2011, Journal of synchrotron radiation.
[55] Marcel L Verdonk,et al. Automated Protein–Ligand Crystallography for Structure‐Based Drug Design , 2006, ChemMedChem.
[56] Nathaniel Echols,et al. The Phenix software for automated determination of macromolecular structures. , 2011, Methods.
[57] M. Wiener,et al. Use of a crystallization robot to set up sitting-drop vapor-diffusion crystallization and in situ crystallization screens , 2000 .
[58] Roberto Dinapoli,et al. PILATUS: A single photon counting pixel detector for X-ray applications , 2009 .
[59] Beat Ernst,et al. From carbohydrate leads to glycomimetic drugs , 2009, Nature Reviews Drug Discovery.
[60] P. Collins,et al. Slow diffusion of lactose out of galectin-3 crystals monitored by X-ray crystallography: possible implications for ligand-exchange protocols. , 2007, Acta crystallographica. Section D, Biological crystallography.
[61] A. Hopkins,et al. Emerging role of surface plasmon resonance in fragment-based drug discovery. , 2011, Future medicinal chemistry.
[62] Glyn Williams,et al. Higher throughput calorimetry: opportunities, approaches and challenges. , 2010, Current opinion in structural biology.
[63] Alan E Mark,et al. Missing fragments: detecting cooperative binding in fragment-based drug design. , 2012, ACS medicinal chemistry letters.
[64] Andrew C Good,et al. Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. , 2012, Journal of medicinal chemistry.
[65] S. Uda,et al. Control of effect on the nucleation rate for hen egg white lysozyme crystals under application of an external ac electric field. , 2011, Langmuir : the ACS journal of surfaces and colloids.
[66] Mike Welch,et al. Potent and selective pyrazole-based inhibitors of B-Raf kinase. , 2008, Bioorganic & medicinal chemistry letters.
[67] Bart Hazes,et al. A nanovolume crystallization robot that creates its crystallization screens on-the-fly. , 2005, Acta crystallographica. Section D, Biological crystallography.
[68] Ge-Fei Hao,et al. Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex. , 2012, Journal of the American Chemical Society.
[69] Gianni Chessari,et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.
[70] Abel Moreno,et al. Novel Protein Crystal Growth Electrochemical Cell For Applications In X-ray Diffraction and Atomic Force Microscopy , 2011 .
[71] M. Krohn,et al. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. , 2010, Journal of medicinal chemistry.
[72] M. Rossmann,et al. Effect of errors, redundancy, and solvent content in the molecular replacement procedure for the structure determination of biological macromolecules. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[73] D. Blow,et al. The detection of sub‐units within the crystallographic asymmetric unit , 1962 .
[74] Edgar Jacoby,et al. Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.
[75] Maria Cristina Burla,et al. IL MILIONE: a suite of computer programs for crystal structure solution of proteins , 2007 .
[76] J. Heng,et al. Crystallization of Proteins at Ultralow Supersaturations Using Novel Three-Dimensional Nanotemplates , 2012 .
[77] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[78] Mark von Itzstein,et al. The war against influenza: discovery and development of sialidase inhibitors , 2007, Nature Reviews Drug Discovery.
[79] Carmelo Giacovazzo,et al. Direct Phasing in Crystallography: Fundamentals and Applications , 1998 .
[80] Anna Vulpetti,et al. Combined use of computational chemistry, NMR screening, and X‐ray crystallography for identification and characterization of fluorophilic protein environments , 2010, Proteins.
[81] M. McLeish,et al. Getting the adrenaline going: crystal structure of the adrenaline-synthesizing enzyme PNMT. , 2001, Structure.
[82] X. Barril,et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. , 2009, Journal of medicinal chemistry.
[83] P. Hirth,et al. Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.
[84] Tom L Blundell,et al. High-throughput X-ray crystallography for drug discovery. , 2004, Current opinion in pharmacology.
[85] S. Forbes,et al. Regulation of Alternative Macrophage Activation by Galectin-31 , 2008, The Journal of Immunology.
[86] J. Rini,et al. Structural and thermodynamic studies on cation-Pi interactions in lectin-ligand complexes: high-affinity galectin-3 inhibitors through fine-tuning of an arginine-arene interaction. , 2005, Journal of the American Chemical Society.
[87] Rob Leurs,et al. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. , 2011, Journal of the American Chemical Society.
[88] M. Millward,et al. Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring , 2013, Front. Oncol..
[89] Phase correction, a new method to solve partially known structures , 1968 .
[90] D. Kassel,et al. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[91] Qiyue Hu,et al. Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery , 2011, J. Comput. Aided Mol. Des..
[92] Maurizio Recanatini,et al. The role of fragment-based and computational methods in polypharmacology. , 2012, Drug discovery today.
[93] Jian Sun,et al. Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering. , 2009, Biochemistry.
[94] Daniel A Erlanson,et al. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. , 2011, Bioorganic & medicinal chemistry letters.